Lilly to buy Calytrix Bio for up to $1.5 billion

Lilly to buy Calytrix Bio for up to $1.5 billion

来源:Reuters发布于 2026-11-16

Eli Lilly has agreed to acquire Calytrix Bio for ​up to $1.5 billion in cash to ‌expand the development of treatments for rare blood cancers, the privately held biotech said ​on Monday.

相关标的:LLY

本文内容来自外部来源,点击「继续访问」将跳转到原始发布站点。